Philippe Bonniaud

Usefulness of omalizumab in ten patients with severe occupational asthma

J. Dalphin, F. Lavaud, C. Leroyer, 2013, Allergy.

Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort

C. Marquette, J. Traclet, R. Borie, 2023, Thorax.

Severe asthma care trajectories: the French RAMSES cohort

C. Tcherakian, M. Russier, Arnaud Bourdin, 2024, ERJ open research.

Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study

L. Olinger, P. Girodet, G. Beltramo, 2023, The Lancet.

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series

E. Ebstein, M. Russier, C. Dupin, 2024, ERJ Open Research.

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

H. Makita, W. Busse, E. Bleecker, 2019, The Lancet. Respiratory medicine.

Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

J. Dalphin, S. Amselem, V. Cottin, 2021, Advances in Therapy.

Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab

Sophie Pereira, Christophe Leroyer, Philippe Bonniaud, 2023, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de Pneumologie de Langue Française (SPLF) (Full length text).

I. Tillie‐Leblond, G. Deslée, J. Dubus, 2016, Revue des maladies respiratoires.